Antibody Engineering & Therapeutics
Antibody therapies have been approved for the treatment of cancer, immune disorders, metabolic, cardiovascular, and infectious diseases. PepTalk’s Antibody Engineering & Therapeutics pipeline offers a forum for protein scientists who are working to discover and develop differentiated biotherapeutics for additional unmet medical needs quickly and efficiently. These programs explore targeting, delivery, conditional activation, masking, fragment based- approaches, alternative scaffolds, antibody drug conjugates, AI, computational design, t cell engagers, promising candidates, and the strong push toward multispecific formats. Join us to explore the important advances in this dynamic field.
January 19
January 20-21
January 21-22
KEYNOTE & FEATURED PRESENTATIONS:
An AI-Guided Brain-Shuttle Platform for Bispecifics and Enhanced CNS Selectivity
John Avera, Scientist II, Protein Sciences, Manifold
Improving the Penetration of Antibodies into Solid Tumors by Reengineering with CreaTap
Zahra Jawad, PhD, CEO & Founder, Creasallis
Structure-Aided Design and Engineering of an FGFR1c x KLB Multispecific AltibodyTM Agonist for MASH
Yang Shen, PhD, Executive Director of Antibody Engineering, Bispecifics, Regeneron
If you are working in the following areas join the PepTalk community:
- Antibody Discovery
- Antibody Engineering
- Antibody Technologies
- Biologics Development
- Biotherapeutics Development
- Cellular Engineering
- Development
- Protein Engineering
- Protein Sciences
- Regulatory Affairs
- Research
- Translational Sciences